CEL-SCI Corp (CVM) shares tumbled 30.44% during early Thursday trading after the biotechnology company announced the pricing of its $10 million public offering, selling 1,111,200 common shares at $9.00 per share.
The offering is expected to close on August 29, 2025, with proceeds intended for general corporate purposes.
CEL-SCI Corp is primarily engaged in research and development utilizing the immune system to treat cancer and other diseases, focusing on activating the immune system to combat cancer and infectious diseases.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments